Zoetis’ (ZTS) “Buy” Rating Reiterated at BTIG Research

BTIG Research reissued their buy rating on shares of Zoetis (NYSE:ZTS) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $160.00 price objective on the stock.

ZTS has been the topic of several other reports. Stifel Nicolaus cut their price target on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research note on Tuesday, November 18th. JPMorgan Chase & Co. cut their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 5th. Morgan Stanley reduced their target price on Zoetis from $211.00 to $175.00 and set an “overweight” rating for the company in a report on Monday, November 10th. Argus restated a “buy” rating and set a $190.00 price target on shares of Zoetis in a research note on Tuesday, September 9th. Finally, UBS Group reduced their price objective on Zoetis from $158.00 to $141.00 and set a “neutral” rating for the company in a research note on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, Zoetis currently has an average rating of “Moderate Buy” and an average price target of $178.89.

Zoetis Stock Performance

Shares of ZTS opened at $118.69 on Wednesday. The stock has a 50 day moving average price of $133.77 and a 200 day moving average price of $147.78. The company has a quick ratio of 2.28, a current ratio of 3.64 and a debt-to-equity ratio of 1.31. The company has a market capitalization of $52.31 billion, a price-to-earnings ratio of 19.98, a price-to-earnings-growth ratio of 2.50 and a beta of 0.97. Zoetis has a 52-week low of $115.25 and a 52-week high of $181.85.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter last year, the company earned $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. Research analysts predict that Zoetis will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, December 2nd. Shareholders of record on Friday, October 31st were given a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date of this dividend was Friday, October 31st. Zoetis’s dividend payout ratio (DPR) is presently 33.67%.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Savvy Advisors Inc. grew its stake in Zoetis by 54.0% in the 2nd quarter. Savvy Advisors Inc. now owns 3,177 shares of the company’s stock valued at $495,000 after acquiring an additional 1,114 shares during the last quarter. Sound Income Strategies LLC lifted its holdings in shares of Zoetis by 54.3% in the second quarter. Sound Income Strategies LLC now owns 432 shares of the company’s stock valued at $67,000 after purchasing an additional 152 shares in the last quarter. Canoe Financial LP lifted its holdings in shares of Zoetis by 859.0% in the second quarter. Canoe Financial LP now owns 13,369 shares of the company’s stock valued at $2,085,000 after purchasing an additional 11,975 shares in the last quarter. Strs Ohio acquired a new stake in shares of Zoetis in the first quarter valued at approximately $22,891,000. Finally, Chicago Partners Investment Group LLC increased its stake in shares of Zoetis by 67.0% during the 2nd quarter. Chicago Partners Investment Group LLC now owns 4,886 shares of the company’s stock worth $750,000 after purchasing an additional 1,961 shares in the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.